Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus

dc.contributor.author Floris, Alberto
dc.contributor.author Piga, Matteo
dc.contributor.author Mangoni, Arduino Aleksander
dc.contributor.author Bortoluzzi, Alessandra
dc.contributor.author Erre, Gian Luca
dc.contributor.author Cauli, Alberto
dc.date.accessioned 2018-03-04T23:20:46Z
dc.date.available 2018-03-04T23:20:46Z
dc.date.issued 2018-02-18
dc.date.updated 2018-02-25T06:52:24Z
dc.description This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en
dc.description.abstract Cardiovascular (CV) morbidity and mortality are a challenge in management of patients with systemic lupus erythematosus (SLE). Higher risk of CV disease in SLE patients is mostly related to accelerated atherosclerosis. Nevertheless, high prevalence of traditional cardiovascular risk factors in SLE patients does not fully explain the increased CV risk. Despite the pathological bases of accelerated atherosclerosis are not fully understood, it is thought that this process is driven by the complex interplay between SLE and atherosclerosis pathogenesis. Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality. Furthermore, HCQ is thought to protect against accelerated atherosclerosis targeting toll-like receptor signaling, cytokine production, T-cell and monocyte activation, oxidative stress, and endothelial dysfunction. HCQ was also described to have beneficial effects on traditional CV risk factors, such as dyslipidemia and diabetes. In conclusion, despite lacking randomized controlled trials unambiguously proving the protection of HCQ against accelerated atherosclerosis and incidence of CV events in SLE patients, evidence analyzed in this review is in favor of its beneficial effect.
dc.identifier.citation Alberto Floris, Matteo Piga, Arduino Aleksander Mangoni, Alessandra Bortoluzzi, Gian Luca Erre, and Alberto Cauli, “Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus,” Mediators of Inflammation, vol. 2018, Article ID 3424136, 11 pages, 2018. doi:10.1155/2018/3424136
dc.identifier.doi https://doi.org/10.1155/2018/3424136
dc.identifier.uri https://doi.org/10.1155/2018/3424136
dc.identifier.uri http://hdl.handle.net/2328/37766
dc.language.iso en en
dc.publisher Hindawi en
dc.rights Copyright © 2018 Alberto Floris et al.
dc.rights.holder Alberto Floris et al.
dc.rights.license CC-BY
dc.title Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus en
dc.type Article en
local.contributor.authorOrcidLookup Mangoni, Arduino Aleksander: https://orcid.org/0000-0001-8699-1412 en_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
MI.2018.3424136.pdf
Size:
869.58 KB
Format:
Adobe Portable Document Format
Description:
Publisher version
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.84 KB
Format:
Item-specific license agreed upon to submission
Description: